Neutralizing antibodies (NAbs) have significant preventive and therapeutic effects. They mainly target the RBD region and can block the binding site of COVID-19 to the ACE2 receptor. COVID-19 NAbs are a low contamination risk and highly specific, which play a crucial role in the research of COVID-19 treatments. Meanwhile,
Recombinant SARS-CoV-2 Spike Protein Receptor Binding Domain from HEK293 cells. The antigens can be used for total antibodies detection to SARS-CoV-2 virus in double-antigen sandwich immunoassay. Our antigens are manufactured to the highest quality standards and are performance guaranteed for the applications listed on the detailed datasheets.
Creative Diagnostics team has tested hundreds of anti-nucleocapsid antibody pairs to recommend you the best pair with proven performance in commercially launched rapid antigen COVID-19 assays.
Principle: COVID-19 Antigen Rapid Test is a rapid membrane-based lateral flow immunoassay for the qualitative detection of SARS-CoV-2 antigens in human nasopharyngeal
Pseudotyped Luciferase/GFP rSARS-CoV-2 Spike is used to test the ability of serum, antibodies, and drugs to neutralize the infectivity of SARS-CoV2 spike protein. Pseudovirus display an antigenically-correct spike protein pseudotyped on replication-incompetent virus particles that contain a heterologous lentiviral (HIV) core.
Pseudotyped Luciferase/GFP rSARS-CoV-2 Spike is capable of